title: [A 6-year study of glycopeptides-resistant enterococci in 3 intensive care units of the University Hospital of Montpellier].
abstract: OBJECTIVE
  The aim of this study was to evaluate the rate of glycopeptides-resistant enterococci (GRE) fecal carriage (species and resistance determinants). Strains isolated between 1999 and 2005 during systematic screening for multiresistant bacteria in patients hospitalized in 3 intensive care units (ICU) of the University Hospital of Montpellier were studied.
  
  
  METHODS
  The systematic screening was weekly performed. Rectal swabs were cultured on D-Coccosel agar medium containing 4 mg/l vancomycin and MICs for vancomycin and teicoplanin were determined by E-test. Strains were subjected to both phenotypic and genotypic identification and vanA, vanB and vanC genes were detected by PCR.
  
  
  RESULTS
  We analyzed 13003 samples for 5113 patients. Among them, 401 (7.84%) patients were GRE carriers with 280 Enterococcus gallinarum (vanC(1)), 102 Enterococcus casseliflavus-flavescens (vanC(2)-C(3)), 5 Enterococcus faecalis (3 vanA, 2 vanB), and 14 Enterococcus faecium (10 vanA, 4 vanB). A unique case of cross contamination between two patients was observed. During the same time, only one strain of GRE was isolated during an infectious process in another unit. Carriage rate of E. faecium and E. faecalis vanA or vanB was 0.37%: 68.4, 21 and 10.6% in the gastrointestinal, in the polyvalent and the respiratory ICU, respectively.
  
  
  CONCLUSIONS
  Our results were in agreement with national data showing a relatively low GRE fecal carriage rate in ICUs, E. faecium vanA being the mainly encountered GRE. Since 2004, GRE detection is increasingly reported in France and an emerging E. faecium vanA clone has been identified during outbreaks. In contrast, only one E. faecium vanB strain has been isolated in our institution since this date and a unique strain of E. faecalis vanA was isolated during an infectious process since 1999. These data underlined the efficacy of transmission prevention measures established when GRE are identified.
authors: Laboratoire de bactériologie, hôpital universitaire Arnaud-de-Villeneuve, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex 05, France. s-godreuil@chu-montpellier.fr
authors: S
authors: S
authors: Godreuil
authors: H
authors: H
authors: Marchandin
authors: A
authors: A
authors: Boulier
authors: A
authors: A
authors: Boumzebra
authors: J
authors: J
authors: Campos
authors: H
authors: H
authors: Jean-Pierre
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D016983:Enterococcus / Q000145:classification / Q000187:drug effects* / Q000235:genetics; D013293:Enterococcus faecalis / Q000187:drug effects / Q000302:isolation & purification; D016984:Enterococcus faecium / Q000187:drug effects / Q000302:isolation & purification; D005602:France; D006020:Glycopeptides / Q000494:pharmacology*; D006785:Hospitals, University; D007362:Intensive Care Units / Q000592:standards*; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D017334:Teicoplanin; D014640:Vancomycin